Secondary solid cancer screening following hematopoietic cell transplantation.

ABSTRACT: Hematopoietic stem cell transplant (HCT) recipients have a substantial risk of developing secondary solid cancers, particularly beyond 5 years after HCT and without reaching a plateau overtime. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal to facilitate implementation of cancer screening appropriate to HCT recipients. The working group reviewed guidelines and methods for cancer screening applicable to the general population and reviewed the incidence and risk factors for secondary cancers after HCT. A consensus approach was used to establish recommendations for individual secondary cancers. The most common sites include oral cavity, skin, breast and thyroid.

SUBMITTER: Inamoto Y 

PROVIDER: S-EPMC4989866 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature